<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39446746</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>29</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2767-3375</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>10</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>PLOS global public health</Title><ISOAbbreviation>PLOS Glob Public Health</ISOAbbreviation></Journal><ArticleTitle>Evaluating the implementation of weekly rifapentine-isoniazid (3HP) for tuberculosis prevention among people living with HIV in Uganda: A qualitative evaluation of the 3HP Options Trial.</ArticleTitle><Pagination><StartPage>e0003347</StartPage><MedlinePgn>e0003347</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0003347</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pgph.0003347</ELocationID><Abstract><AbstractText>Three months of isoniazid-rifapentine (3HP) is being scaled up for tuberculosis (TB) preventive treatment (TPT) among people living with HIV (PLHIV) in high-burden settings. More evidence is needed to identify factors influencing successful 3HP delivery. We conducted a qualitative assessment of 3HP delivery nested within the 3HP Options Trial, which compared three optimized strategies for delivering 3HP: facilitated directly observed therapy (DOT), facilitated self-administered therapy (SAT), and patient choice between facilitated DOT and facilitated SAT at the Mulago HIV/AIDS clinic in Kampala, Uganda. We conducted 72 in-depth interviews among PLHIV purposively selected to investigate factors influencing 3HP acceptance and completion. We conducted ten key informant interviews with healthcare providers (HCPs) involved in 3HP delivery to identify facilitators and barriers at the clinic level. We used post-trial 3HP delivery data to assess sustainability. We used thematic analysis (inductive and deductive) to align the emergent themes with the RE-AIM framework dimensions to report implementation outcomes. Understanding the need for TPT, once-weekly dosing, shorter duration, and perceived 3HP safety enhanced acceptance overall. Treatment monitoring by HCPs and reduced risk of HIV status disclosure enabled DOT acceptance. Dosing autonomy enabled SAT acceptance. Switching between DOT and SAT as needed enabled acceptance of patient choice. Dosing reminders, reimbursement for clinical visits, and social support enabled 3HP completion; pill burden, side effects, and COVID-19-related treatment restrictions hindered completion. All HCPs were trained and participated in 3HP delivery with high fidelity. Training, care integration, prior TPT experience with daily isoniazid, and few 3HP-related serious adverse events enabled adoption, whereas initial concerns about 3HP safety among HCPs, and COVID-19 treatment disruptions delayed 3HP adoption. Refresher training and collaboration among HCPs enabled implementation whereas limited diagnostic facilities for adverse events at the clinic hindered implementation. SAT was modified post-trial; DOT was discontinued due to inadequate ongoing financial support beyond the study period. Facilitated delivery strategies made 3HP treatment convenient for PLHIV and were feasible and implemented with high fidelity by HCPs. However, the costs of 3HP facilitation may limit wider scale-up. Trial registration: ClinicalTrials.gov (NCT03934931); Registered 2nd May 2019; https://clinicaltrials.gov/study/NCT03934931?id = NCT03934931&amp;rank = 1.</AbstractText><CopyrightInformation>Copyright: © 2024 Musinguzi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Musinguzi</LastName><ForeName>Allan</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-9941-6433</Identifier><AffiliationInfo><Affiliation>Infectious Diseases Research Collaboration, Kampala, Uganda.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kasidi</LastName><ForeName>Joan R</ForeName><Initials>JR</Initials><Identifier Source="ORCID">0000-0002-4761-462X</Identifier><AffiliationInfo><Affiliation>Infectious Diseases Research Collaboration, Kampala, Uganda.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kadota</LastName><ForeName>Jillian L</ForeName><Initials>JL</Initials><Identifier Source="ORCID">0000-0003-4568-8681</Identifier><AffiliationInfo><Affiliation>Center for Tuberculosis and Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Welishe</LastName><ForeName>Fred</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Infectious Diseases Research Collaboration, Kampala, Uganda.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakitende</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Infectious Diseases Research Collaboration, Kampala, Uganda.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akello</LastName><ForeName>Lydia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Infectious Diseases Research Collaboration, Kampala, Uganda.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakimuli</LastName><ForeName>Jane</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Infectious Diseases Research Collaboration, Kampala, Uganda.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kunihira</LastName><ForeName>Lynn T</ForeName><Initials>LT</Initials><AffiliationInfo><Affiliation>Uganda Tuberculosis Implementation Research Consortium, Walimu, Kampala, Uganda.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Opira</LastName><ForeName>Bishop</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Infectious Diseases Research Collaboration, Kampala, Uganda.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baik</LastName><ForeName>Yeonsoo</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-7016-0438</Identifier><AffiliationInfo><Affiliation>Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Devika</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-1479-3588</Identifier><AffiliationInfo><Affiliation>Department of Surgery, University of California San Francisco, San Francisco, California, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Better Lab, University of California, San Francisco, San Francisco, California, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sammann</LastName><ForeName>Amanda</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-8044-7165</Identifier><AffiliationInfo><Affiliation>Department of Surgery, University of California San Francisco, San Francisco, California, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Better Lab, University of California, San Francisco, San Francisco, California, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berger</LastName><ForeName>Christopher A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Center for Tuberculosis and Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aschmann</LastName><ForeName>Hélène E</ForeName><Initials>HE</Initials><Identifier Source="ORCID">0000-0003-1234-4321</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics and Division of Pulmonary and Critical Care Medicine, University of California San Francisco, San Francisco, California, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nahid</LastName><ForeName>Payam</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-2811-1311</Identifier><AffiliationInfo><Affiliation>Center for Tuberculosis and Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belknap</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Denver Health and Hospital Authority and Division of Infectious Diseases, Department of Medicine, University of Colorado, Denver, Colorado, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kamya</LastName><ForeName>Moses R</ForeName><Initials>MR</Initials><Identifier Source="ORCID">0000-0001-9106-4234</Identifier><AffiliationInfo><Affiliation>Infectious Diseases Research Collaboration, Kampala, Uganda.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, School of Medicine, Makerere University College of Health Sciences, Kampala, Uganda.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Handley</LastName><ForeName>Margaret A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0001-5034-2111</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Phillips</LastName><ForeName>Patrick P J</ForeName><Initials>PPJ</Initials><Identifier Source="ORCID">0000-0002-6336-7024</Identifier><AffiliationInfo><Affiliation>Center for Tuberculosis and Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiwanuka</LastName><ForeName>Noah</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0003-2471-9290</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, School of Public Health, Makerere University College of Health Sciences, Kampala, Uganda.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katamba</LastName><ForeName>Achilles</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-2347-4183</Identifier><AffiliationInfo><Affiliation>Uganda Tuberculosis Implementation Research Consortium, Walimu, Kampala, Uganda.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Epidemiology &amp; Biostatistics Unit, Department of Medicine, Makerere University College of Health Sciences, Kampala, Uganda.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dowdy</LastName><ForeName>David W</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>Uganda Tuberculosis Implementation Research Consortium, Walimu, Kampala, Uganda.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cattamanchi</LastName><ForeName>Adithya</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-6553-2601</Identifier><AffiliationInfo><Affiliation>Center for Tuberculosis and Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Uganda Tuberculosis Implementation Research Consortium, Walimu, Kampala, Uganda.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Pulmonary Diseases and Critical Care Medicine, University of California Irvine, Irvine, California, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Semitala</LastName><ForeName>Fred C</ForeName><Initials>FC</Initials><Identifier Source="ORCID">0000-0002-0624-7640</Identifier><AffiliationInfo><Affiliation>Infectious Diseases Research Collaboration, Kampala, Uganda.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, School of Medicine, Makerere University College of Health Sciences, Kampala, Uganda.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Makerere University Joint AIDS Program, Kampala, Uganda.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katahoire</LastName><ForeName>Anne R</ForeName><Initials>AR</Initials><Identifier Source="ORCID">0000-0003-3520-070X</Identifier><AffiliationInfo><Affiliation>Child Health and Development Center, School of Medicine, Makerere University College of Health Sciences, Kampala, Uganda.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT03934931</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>R01 HL144406</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLOS Glob Public Health</MedlineTA><NlmUniqueID>9918283779606676</NlmUniqueID><ISSNLinking>2767-3375</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>medRxiv. 2024 Aug 22:2024.08.19.24308041. doi: 10.1101/2024.08.19.24308041</RefSource><PMID Version="1">39314926</PMID></CommentsCorrections></CommentsCorrectionsList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>24</Day><Hour>22</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>24</Day><Hour>22</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>24</Day><Hour>13</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39446746</ArticleId><ArticleId IdType="pmc">PMC11500930</ArticleId><ArticleId IdType="doi">10.1371/journal.pgph.0003347</ArticleId><ArticleId IdType="pii">PGPH-D-24-01188</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization Global tuberculosis report 2023. Licence: CC BY-NC-SA 3.0 IGO. 2023.</Citation></Reference><Reference><Citation>Millington K.A., White R.G., Lipman M., McQuaid C.F., Hauser J., Wooding V., et al.., The 2023 UN high-level meeting on tuberculosis: renewing hope, momentum, and commitment to end tuberculosis. 2024. 12(1): p. 10–13. doi: 10.1016/S2213-2600(23)00409-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(23)00409-5</ArticleId><ArticleId IdType="pubmed">37972624</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterling T.R., Scott N.A., Miro J.M., Calvet G., La Rosa A., Infante R., et al.., Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons. AIDS (London, England), 2016. 30(10): p. 1607–1615. doi: 10.1097/QAD.0000000000001098</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QAD.0000000000001098</ArticleId><ArticleId IdType="pmc">PMC4899978</ArticleId><ArticleId IdType="pubmed">27243774</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanes-Lane M., Ortiz-Brizuela E., Campbell J.R., Benedetti A., Churchyard G., Oxlade O., et al.., Tuberculosis preventive therapy for people living with HIV: A systematic review and network meta-analysis. PLOS Medicine, 2021. 18(9): p. e1003738. doi: 10.1371/journal.pmed.1003738</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1003738</ArticleId><ArticleId IdType="pmc">PMC8439495</ArticleId><ArticleId IdType="pubmed">34520459</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization, Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. 2018, World Health Organization.</Citation><ArticleIdList><ArticleId IdType="pubmed">30277688</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinson N.A., Barnes G.L., Moulton L.H., Msandiwa R., Hausler H., Ram M., et al.., New Regimens to Prevent Tuberculosis in Adults with HIV Infection. New England Journal of Medicine, 2011. 365(1): p. 11–20. doi: 10.1056/NEJMoa1005136</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1005136</ArticleId><ArticleId IdType="pmc">PMC3407678</ArticleId><ArticleId IdType="pubmed">21732833</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferguson O., Jo Y., Pennington J., Johnson K., Chaisson R.E., Churchyard G., et al.., Cost-effectiveness of one month of daily isoniazid and rifapentine versus three months of weekly isoniazid and rifapentine for prevention of tuberculosis among people receiving antiretroviral therapy in Uganda. 2020. 23(10): p. e25623. doi: 10.1002/jia2.25623</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jia2.25623</ArticleId><ArticleId IdType="pmc">PMC7569168</ArticleId><ArticleId IdType="pubmed">33073520</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai W.A., Brethour K., D’Silva O., Chaisson R.E., and Zwerling A.A., Cost-effectiveness of 3-months isoniazid and rifapentine compared to 9-months isoniazid for latent tuberculosis infection: a systematic review. BMC Public Health, 2022. 22(1): p. 2292. doi: 10.1186/s12889-022-14766-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12889-022-14766-6</ArticleId><ArticleId IdType="pmc">PMC9727859</ArticleId><ArticleId IdType="pubmed">36476206</ArticleId></ArticleIdList></Reference><Reference><Citation>Belknap R., Holland D., Feng P.-J., Millet J.-P., Caylà J.A., Martinson N.A., et al.., Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection. Annals of Internal Medicine, 2017. 167(10): p. 689–697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5766341</ArticleId><ArticleId IdType="pubmed">29114781</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadota J.L., Musinguzi A., Nabunje J., Welishe F., Ssemata J.L., Bishop O., et al.., Protocol for the 3HP Options Trial: a hybrid type 3 implementation-effectiveness randomized trial of delivery strategies for short-course tuberculosis preventive therapy among people living with HIV in Uganda. Implementation Science, 2020. 15(1): p. 65. doi: 10.1186/s13012-020-01025-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13012-020-01025-8</ArticleId><ArticleId IdType="pmc">PMC7425004</ArticleId><ArticleId IdType="pubmed">32787925</ArticleId></ArticleIdList></Reference><Reference><Citation>Semitala F.C., Musinguzi A., Ssemata J., Welishe F., Nabunje J., Kadota J.L., et al.., Acceptance and completion of rifapentine-based TB preventive therapy (3HP) among people living with HIV (PLHIV) in Kampala, Uganda—patient and health worker perspectives. 2021. 2(1): p. 1–12. doi: 10.1186/s43058-021-00173-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s43058-021-00173-2</ArticleId><ArticleId IdType="pmc">PMC8247167</ArticleId><ArticleId IdType="pubmed">34193311</ArticleId></ArticleIdList></Reference><Reference><Citation>Semitala F.C., Kadota J., Musinguzi A., Nabunje J., Welishe F., Nakitende A., et al.., Completion of Isoniazid-Rifapentine (3HP) for tuberculosis (TB) prevention among people living with HIV (PLHIV): interim analysis of the 3HP Options Trial. PLoS Med, 2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8726462</ArticleId><ArticleId IdType="pubmed">34914696</ArticleId></ArticleIdList></Reference><Reference><Citation>Semitala F.C., Kadota J.L., Musinguzi A., Welishe F., Nakitende A., Akello L., et al.., Comparison of 3 optimized delivery strategies for completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV in Uganda: A single-center randomized trial. PLOS Medicine, 2024. 21(2): p. e1004356. doi: 10.1371/journal.pmed.1004356</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1004356</ArticleId><ArticleId IdType="pmc">PMC10914279</ArticleId><ArticleId IdType="pubmed">38377166</ArticleId></ArticleIdList></Reference><Reference><Citation>Glasgow R.E., Vogt T.M., and Boles S.M., Evaluating the public health impact of health promotion interventions: the RE-AIM framework. 1999. 89(9): p. 1322–1327. doi: 10.2105/ajph.89.9.1322</Citation><ArticleIdList><ArticleId IdType="doi">10.2105/ajph.89.9.1322</ArticleId><ArticleId IdType="pmc">PMC1508772</ArticleId><ArticleId IdType="pubmed">10474547</ArticleId></ArticleIdList></Reference><Reference><Citation>Glasgow R.E., Harden S.M., Gaglio B., Rabin B., Smith M.L., Porter G.C., et al.., RE-AIM Planning and Evaluation Framework: Adapting to New Science and Practice With a 20-Year Review. 2019. 7. doi: 10.3389/fpubh.2019.00064</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2019.00064</ArticleId><ArticleId IdType="pmc">PMC6450067</ArticleId><ArticleId IdType="pubmed">30984733</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers P. and Woolcock M.J.C.F.W.P.S., Process and Implementation Evaluations: A Primer. 2023.</Citation></Reference><Reference><Citation>Tong A., Sainsbury P., and Craig J., Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. International Journal for Quality in Health Care, 2007. 19(6): p. 349–357. doi: 10.1093/intqhc/mzm042</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/intqhc/mzm042</ArticleId><ArticleId IdType="pubmed">17872937</ArticleId></ArticleIdList></Reference><Reference><Citation>Cross A., Gupta N., Liu B., Nair V., Kumar A., Kuttan R., et al.. 99DOTS: a low-cost approach to monitoring and improving medication adherence. in Proceedings of the Tenth International Conference on Information and Communication Technologies and Development. 2019.</Citation></Reference><Reference><Citation>Hennink M. and Kaiser B.N., Sample sizes for saturation in qualitative research: A systematic review of empirical tests. Social Science &amp; Medicine, 2022. 292: p. 114523. doi: 10.1016/j.socscimed.2021.114523</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.socscimed.2021.114523</ArticleId><ArticleId IdType="pubmed">34785096</ArticleId></ArticleIdList></Reference><Reference><Citation>Hennink M.M., Kaiser B.N., and Marconi V.C., Code Saturation Versus Meaning Saturation: How Many Interviews Are Enough? Qual Health Res, 2017. 27(4): p. 591–608. doi: 10.1177/1049732316665344</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1049732316665344</ArticleId><ArticleId IdType="pmc">PMC9359070</ArticleId><ArticleId IdType="pubmed">27670770</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhakal K., NVivo. J Med Libr Assoc, 2022. 110(2): p. 270–272. doi: 10.5195/jmla.2022.1271</Citation><ArticleIdList><ArticleId IdType="doi">10.5195/jmla.2022.1271</ArticleId><ArticleId IdType="pmc">PMC9014916</ArticleId><ArticleId IdType="pubmed">35440911</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtrop J.S., Rabin B.A., and Glasgow R.E., Qualitative approaches to use of the RE-AIM framework: rationale and methods. BMC Health Services Research, 2018. 18(1): p. 177. doi: 10.1186/s12913-018-2938-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12913-018-2938-8</ArticleId><ArticleId IdType="pmc">PMC5851243</ArticleId><ArticleId IdType="pubmed">29534729</ArticleId></ArticleIdList></Reference><Reference><Citation>Heyd A., Heffernan C., Storey K., Wild T.C., and Long R., Treating latent tuberculosis infection (LTBI) with isoniazid and rifapentine (3HP) in an inner-city population with psychosocial barriers to treatment adherence: A qualitative descriptive study. PLOS Global Public Health, 2021. 1(12): p. e0000017. doi: 10.1371/journal.pgph.0000017</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgph.0000017</ArticleId><ArticleId IdType="pmc">PMC10021900</ArticleId><ArticleId IdType="pubmed">36962068</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuen C.M., Millones A.K., Galea J.T., Puma D., Jimenez J., Lecca L., et al.., Toward patient-centered tuberculosis preventive treatment: preferences for regimens and formulations in Lima, Peru. BMC Public Health, 2021. 21(1): p. 121. doi: 10.1186/s12889-020-10098-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12889-020-10098-5</ArticleId><ArticleId IdType="pmc">PMC7802335</ArticleId><ArticleId IdType="pubmed">33430823</ArticleId></ArticleIdList></Reference><Reference><Citation>Muddu M., Semitala F.C., Kimera I.D., Musimbaggo D.J., Mbuliro M., Ssennyonjo R., et al.., Using the RE-AIM framework to evaluate the implementation and effectiveness of a WHO HEARTS-based intervention to integrate the management of hypertension into HIV care in Uganda: a process evaluation. Implementation Science Communications, 2023. 4(1): p. 102. doi: 10.1186/s43058-023-00488-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s43058-023-00488-2</ArticleId><ArticleId IdType="pmc">PMC10463385</ArticleId><ArticleId IdType="pubmed">37626415</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorothy T.C., Rutendo B.L.Z.-G., and Charles C., Organizational Readiness for the Implementation of a Three-Month Short-Course TB Preventive Therapy Regimen (3HP) in Four Health Care Facilities in Zimbabwe in 2020: A Mixed Methods Study. medRxiv, 2021: p. 2021.05.26.21256736.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>